Citadel Advisors
LENZ

Citadel Advisors’s LENZ Therapeutics LENZ Stock Holding History

Citadel Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$689K Buy
75,300
+55,400
+278% +$778K ﹤0.01% 8522
2025
Q4 		$318K Buy
19,900
+5,500
+38% +$160K ﹤0.01% 10001
2025
Q3 		$671K Buy
+14,400
New +$530K ﹤0.01% 8431
2023
Q4 		– Sell
-100
Closed -$1.74K – 15411
2023
Q3 		$1.74K Sell
100
-414
-81% -$7.2K ﹤0.01% 13816
2023
Q2 		$9.36K Sell
514
-586
-53% -$11.7K ﹤0.01% 13257
2023
Q1 		$18.9K Sell
1,100
-3,114
-74% -$50.4K ﹤0.01% 13109
2022
Q4 		$97.9K Sell
4,214
-643
-13% -$14.9K ﹤0.01% 11250
2022
Q3 		$108K Buy
+4,857
New +$116K ﹤0.01% 11020

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Citadel Advisors's LENZ Position: Q1 2026 in Review

Citadel Advisors sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 80,574 shares — an estimated $1.13M sold.

Citadel Advisors first reported a position in LENZ in Q2 2021 and held it in 15 quarters. The position peaked at $38.9M in Q2 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Citadel Advisors reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 80,574 LENZ Therapeutics shares in Q1 2026, an estimated $1.13M.
  • Citadel Advisors first reported a position in LENZ Therapeutics in Q2 2021 and held it in 15 quarters.
  • Citadel Advisors's LENZ Therapeutics position peaked at $38.9M in Q2 2021.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.